443 related articles for article (PubMed ID: 17539736)
21. Roles of chemokine receptor CX3CR1 in maintaining murine bone homeostasis through the regulation of both osteoblasts and osteoclasts.
Hoshino A; Ueha S; Hanada S; Imai T; Ito M; Yamamoto K; Matsushima K; Yamaguchi A; Iimura T
J Cell Sci; 2013 Feb; 126(Pt 4):1032-45. PubMed ID: 23264747
[TBL] [Abstract][Full Text] [Related]
22. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
23. Effect of osteoblast-targeted expression of bcl-2 in bone: differential response in male and female mice.
Pantschenko AG; Zhang W; Nahounou M; McCarthy MB; Stover ML; Lichtler AC; Clark SH; Gronowicz GA
J Bone Miner Res; 2005 Aug; 20(8):1414-29. PubMed ID: 16007339
[TBL] [Abstract][Full Text] [Related]
24. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
25. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
26. The effects of serine proteinase inhibitors on bone resorption in vitro.
Tumber A; Papaioannou S; Breckon J; Meikle MC; Reynolds JJ; Hill PA
J Endocrinol; 2003 Sep; 178(3):437-47. PubMed ID: 12967336
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
[TBL] [Abstract][Full Text] [Related]
28. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.
Kim JY; Cheon YH; Kwak SC; Baek JM; Yoon KH; Lee MS; Oh J
J Bone Miner Res; 2014 Jul; 29(7):1541-53. PubMed ID: 25832436
[TBL] [Abstract][Full Text] [Related]
29. Regulation of bone mass and osteoclast function depend on the F-actin modulator SWAP-70.
Garbe AI; Roscher A; Schüler C; Lutter AH; Glösmann M; Bernhardt R; Chopin M; Hempel U; Hofbauer LC; Rammelt S; Egerbacher M; Erben RG; Jessberger R
J Bone Miner Res; 2012 Oct; 27(10):2085-96. PubMed ID: 22648978
[TBL] [Abstract][Full Text] [Related]
30. Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio.
Tudpor K; van der Eerden BC; Jongwattanapisan P; Roelofs JJ; van Leeuwen JP; Bindels RJ; Hoenderop JG
Bone; 2015 Mar; 72():14-22. PubMed ID: 25460576
[TBL] [Abstract][Full Text] [Related]
31. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
32. Increased bone formation in mice lacking plasminogen activators.
Daci E; Everts V; Torrekens S; Van Herck E; Tigchelaar-Gutterr W; Bouillon R; Carmeliet G
J Bone Miner Res; 2003 Jul; 18(7):1167-76. PubMed ID: 12854826
[TBL] [Abstract][Full Text] [Related]
33. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
34. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects.
Kenner L; Hoebertz A; Beil FT; Keon N; Karreth F; Eferl R; Scheuch H; Szremska A; Amling M; Schorpp-Kistner M; Angel P; Wagner EF
J Cell Biol; 2004 Feb; 164(4):613-23. PubMed ID: 14769860
[TBL] [Abstract][Full Text] [Related]
35. Role of CSF-1 in bone and bone marrow development.
Cecchini MG; Hofstetter W; Halasy J; Wetterwald A; Felix R
Mol Reprod Dev; 1997 Jan; 46(1):75-83; discussion 83-4. PubMed ID: 8981367
[TBL] [Abstract][Full Text] [Related]
36. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
Kassem M
APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
[TBL] [Abstract][Full Text] [Related]
37. Osteoblast and osteoclast differentiation in an in vitro three-dimensional model of bone.
Tortelli F; Pujic N; Liu Y; Laroche N; Vico L; Cancedda R
Tissue Eng Part A; 2009 Sep; 15(9):2373-83. PubMed ID: 19292676
[TBL] [Abstract][Full Text] [Related]
38. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts.
Lean JM; Murphy C; Fuller K; Chambers TJ
J Cell Biochem; 2002; 87(4):386-93. PubMed ID: 12397598
[TBL] [Abstract][Full Text] [Related]
39. GPCR kinase 2 interacting protein 1 (GIT1) regulates osteoclast function and bone mass.
Menon P; Yin G; Smolock EM; Zuscik MJ; Yan C; Berk BC
J Cell Physiol; 2010 Nov; 225(3):777-85. PubMed ID: 20568227
[TBL] [Abstract][Full Text] [Related]
40. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis.
Zhao C; Irie N; Takada Y; Shimoda K; Miyamoto T; Nishiwaki T; Suda T; Matsuo K
Cell Metab; 2006 Aug; 4(2):111-21. PubMed ID: 16890539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
